Delova Biotech

Executive Summary

Delova Biotech is a Shanghai-based biopharmaceutical company specializing in the development of next-generation biologic therapies for cancer, primarily bispecific antibodies and antibody-drug conjugates (ADCs). Founded in 2018, the company leverages proprietary antibody engineering platforms to design molecules with enhanced tumor targeting and immune system engagement. Its pipeline, currently in Phase 1 stage, aims to address unmet needs in oncology, with a focus on bringing novel therapies to patients in China and globally. Despite its early stage, Delova's differentiated approach positions it in a competitive landscape, with potential for partnerships or licensing deals given the strong interest in bispecifics and ADCs. The company's private status and lack of disclosed financials make valuation uncertain, but its technology platforms and strategic location in China's growing biotech hub provide a foundation for future growth. Key risks include clinical trial outcomes, regulatory hurdles, and competition from larger players. Overall, Delova presents an emerging opportunity in the oncology biologics space, albeit with typical early-stage volatility.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 clinical trial initiation for lead bispecific antibody candidate70% success
• Q4 2026Presentation of preclinical data for ADC program at a major oncology conference60% success
• 2026Potential strategic partnership or licensing deal for China or ex-China rights40% success